(Liver Cancer) Is Tecentriq + Avastin Effective?
(Liver Cancer) Is Tecentriq + Avastin Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Liver Cancer) Is Tecentriq + Avastin Effective?
- June 5, 2023
- 1 min read
On April 16, 2023, Roche announced the latest research data from the IMbrave050 Phase III clinical trial evaluating Tecentriq + Avastin for hepatocellular carcinoma patients at high risk of recurrence after curative surgery or radiofrequency ablation.
The IMbrave050 Phase III clinical trial divided hepatocellular carcinoma patients at high risk of recurrence after curative surgery or radiofrequency ablation (N=668) into the Tecentriq (1,200 mg) + Avastin (15 mg/kg) group (once every three weeks, for up to 1 year or 17 treatment cycles) and the active surveillance group. The primary endpoint was recurrence-free survival, with secondary endpoints including overall survival and recurrence-free survival in PD-L1-positive patients.
At a median follow-up of 17.4 months, the primary endpoint recurrence-free survival showed a 28% reduction in recurrence risk for the Tecentriq + Avastin group compared to the active surveillance group. The secondary endpoint overall survival had not yet been reached.
Regarding safety, the adverse event profile of Tecentriq + Avastin was consistent with the safety profiles observed in other clinical trials.
Based on the IMbrave050 trial results, Levi Garraway, Chief Medical Officer and Head of Global Product Development at Roche, stated that Tecentriq + Avastin is already the standard treatment for unresectable hepatocellular carcinoma, and this trial shows the potential for extending its use to other hepatocellular carcinoma patients. Complete data are anticipated in the future.
Source: https://www.roche.com/media/releases/med-cor-2023-04-16
-
Investigational Drugs
-
Immunotherapy
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Results in Phase II Clinical Trial. (Lung Cancer) Is Trastuzumab deruxtecan Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is the Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.